| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
41,630,000 |
| Market
Cap: |
26.95(M) |
| Last
Volume: |
204,752 |
Avg
Vol: |
419,925 |
| 52
Week Range: |
$0.6474 - $0.6474 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Lannett primarily develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. Co.'s primary products include: Amphetamine IR Tablets, which are used to treat Attention Deficit Hyperactivity Disorder (ADHD) and narcolepsy; Amphetamine ER Capsules, which are indicated for use to treat ADHD; Dicyclomine Tablets, which are indication for the treatment of functional bowel disorder and irritable bowel syndrome; Fluphenazine Tablets, which are used for the management of manifestations of psychotic disorders; and Levothyroxine Capsules, which are soft gel capsules used to treat patients with hypothyroidism and other conditions.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
166,159 |
| Total Buy Value |
$0 |
$0 |
$0 |
$81,668 |
| Total People Bought |
0 |
0 |
0 |
4 |
| Total Buy Transactions |
0 |
0 |
0 |
4 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-31 |
2023-12-29 |
2023-06-30 |
2022-06-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Galvan Martin P |
VP of Finance & CFO |
• – – |
2014-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
32,000 |
|
- |
|
| Schreck William |
COO |
• – – |
2014-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
1,225 |
219,081 |
|
- |
|
| Smith Kevin |
Vice President |
• – – |
2014-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
62,672 |
|
- |
|
| Bedrosian Arthur P |
President and CEO |
• • – |
2014-04-24 |
4 |
D |
$34.66 |
$25,614 |
D/D |
(739) |
649,877 |
|
- |
|
| Drabik David A |
Director |
– • – |
2014-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
1,875 |
25,625 |
|
- |
|
| Farber Jeffrey |
Director |
– • – |
2014-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
1,875 |
420,595 |
|
- |
|
| Maher James M. |
Director |
– • – |
2014-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
1,875 |
8,625 |
|
- |
|
| Taveira Paul |
Director |
– • – |
2014-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
1,875 |
16,625 |
|
- |
|
| Bedrosian Arthur P |
President and CEO |
• • – |
2014-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
1,875 |
650,616 |
|
- |
|
509 Records found
|
|
Page 21 of 21 |
|
|
